Anwold
Anwold runs genomics pipelines for hospitals that need reproducibility and an audit trail more than they need raw speed.
Why we investedHealth / Seed 2020
What we saw in Anwold.
Research hospitals were rebuilding the same pipelines every few years, each time losing the ability to reproduce results from the last version.
Owen is a clinical geneticist who cared about provenance first. Sara built the compute layer that makes it affordable.
The buyer is slow and grant funded. The contracts, once signed, tend to last a decade.
At a glance
The company in short.
- Founded
- 2019, Cambridge
- Founders
- Dr Owen Aldridge and Sara Kim
- Sector
- Health
- First cheque
- Seed, 2020
- Our role
- Led the seed
- Partner
- Priya Ramanathan
- Status
- Active
- Website
- anwold.bio
Milestones
How Anwold has moved.
2019
Founded in Cambridge alongside a genomics research programme.
2020
Rifatela led the $2.8M seed.
2024
Running pipelines for 26 research hospitals.
More in Health
Companies working on nearby problems.
Building something in this space?
We back one or two companies a year in each sector. If that is you, send us a short note.